Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Castration-resistant prostate cancer (CRPC) growth is driven by persistent androgen receptor (AR) signaling.
• Aberrations such as intracrine androgen production and AR amplification are key drivers in CRPC.
• Despite castration, prostate cancer retains dependence on the AR axis.

Purpose of the Study:

• To review preclinical and clinical findings in androgen-androgen receptor (AR) axis-targeted therapies for CRPC.
• To categorize AR-targeted therapies based on their mechanism of action (prereceptor vs. receptor level).
• To highlight the clinical efficacy of novel AR-targeted agents.

Main Methods:

• Review of scientific literature and clinical trial data.
• Categorization of therapies targeting androgen production (prereceptor) and AR directly (receptor level).
• Analysis of clinical data from abiraterone acetate (Phase III) and MDV-3100 (Phase II).

Main Results:

• New therapies targeting the AR axis demonstrate significant clinical activity in CRPC.
• Abiraterone acetate and MDV-3100 show clinical benefit by targeting persistent AR signaling.
• Targeting androgen synthesis and AR aberrations yields positive clinical outcomes.

Conclusions:

• CRPC remains therapeutically sensitive to interventions targeting the androgen-AR axis.
• Targeting AR signaling pathways provides significant clinical benefit for patients with CRPC.
• Ongoing research focuses on optimizing treatment timing and understanding resistance mechanisms.